Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H26N7O17P3.Na.H |
| Molecular Weight | 765.3868 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[Na+].NC(=O)C1=C[N+](=CC=C1)[C@@H]2O[C@H](COP([O-])(=O)OP([O-])(=O)OC[C@H]3O[C@H]([C@H](OP(O)([O-])=O)[C@@H]3O)N4C=NC5=C4N=CN=C5N)[C@@H](O)[C@H]2O
InChI
InChIKey=JNUMDLCHLVUHFS-QYZPTAICSA-M
InChI=1S/C21H28N7O17P3.Na/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32;/h1-4,7-8,10-11,13-16,20-21,29-31H,5-6H2,(H7-,22,23,24,25,32,33,34,35,36,37,38,39);/q;+1/p-1/t10-,11-,13-,14-,15-,16-,20-,21-;/m1./s1
| Molecular Formula | C21H26N7O17P3 |
| Molecular Weight | 741.3891 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H |
| Molecular Weight | 1.0079 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
NADIDE (NAD+) is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. NADIDE was marketed under the brand name Enada. Although Enada (NADH) is marketed as a nutritional supplement, Birkmayer
Pharmaceuticals has launched two clinical trials to prove scientifically that Enada is effective.
Before these studies could get started they had to also prove to the Food and Drug Administration (FDA) that the stable oral form of Enada (NADH) is a safe substance.
Since the mid-‘80s more than 3,000 parkinsonian patients have received NADH, either as
intravenous infusion or in the form of oral tablets. Enada (NADH) is the world‘s first and only stabilized, absorbable, patented, tablet-form
NADH dietary supplement. It is now available to everyone whose lifestyle demands increased
energy, vitality and mental clarity. In other words, it is beneficial not only for patients
suffering from chronic fatigue syndrome, Alzheimer‘s disease, depression or Parkinson‘s
disease, but for any normal, healthy individual whose lifestyle demands more energy. NADIDE (NADH) may be considered as a therapeutic adjunct for
cancer patients to protect them against the general toxic effects of substances such as
doxorubicin or cisplatin by stimulating the DNA repair system and by promoting normal cellular
biosynthetic responses after chemotherapy. NADH seems to exhibit a chemo preventive effect.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [The effect of guanosyl-5'-monophosphate on metabolic processes in rats with experimental myocarditis]. | 1990 Sep-Oct |
|
| The novel aldehyde dehydrogenase gene, ALDH5, encodes an active aldehyde dehydrogenase enzyme. | 1995 Jun 6 |
|
| L-lactate dehydrogenase A4- and A3B isoforms are bona fide peroxisomal enzymes in rat liver. Evidence for involvement in intraperoxisomal NADH reoxidation. | 1996 Feb 16 |
|
| Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation. | 1996 May 7 |
|
| NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis. | 2005 |
|
| Complex I regulates mutant mitochondrial aldehyde dehydrogenase activity and voluntary ethanol consumption in rats. | 2005 Jan |
|
| Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies. | 2005 Jul |
|
| PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. | 2005 Mar 17 |
|
| Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. | 2005 Mar 18 |
|
| A kinetic study on the lactoperoxidase catalyzed oxidation of estrogens. | 2006 Dec |
|
| Molecular cloning of a novel type of rat cytoplasmic 17beta-hydroxysteroid dehydrogenase distinct from the type 5 isozyme. | 2006 Jun |
|
| Expression of a novel P275L variant of NADH:cytochrome b5 reductase gives functional insight into the conserved motif important for pyridine nucleotide binding. | 2006 Mar 1 |
|
| TRPM2 activation by cyclic ADP-ribose at body temperature is involved in insulin secretion. | 2006 May 3 |
|
| Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes. | 2006 Oct 20 |
|
| 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly(ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines. | 2007 Aug |
|
| Dietary protein level and dietary interaction affect quinolinic acid concentration in rats. | 2007 Mar |
|
| Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons. | 2009 |
|
| Mechanism of thiol-supported arsenate reduction mediated by phosphorolytic-arsenolytic enzymes: I. The role of arsenolysis. | 2009 Aug |
|
| Saline-linked surface radiofrequency ablation: a safe and effective method of surface ablation of hepatic metastatic colorectal cancer. | 2009 Jul |
|
| Protective role of estrogen receptor-alpha on lower chlorinated PCB congener-induced DNA damage and repair in human tumoral breast cells. | 2009 Jul 10 |
|
| Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. | 2009 Jun |
|
| The conserved R166 residue of ALDH5A (succinic semialdehyde dehydrogenase) has multiple functional roles. | 2009 Mar 16 |
|
| Biochemical characterization of human epidermal retinol dehydrogenase 2. | 2009 Mar 16 |
|
| Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. | 2009 Sep |
|
| Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells. | 2010 Aug 15 |
|
| Identification of the aryl hydrocarbon receptor target gene TiPARP as a mediator of suppression of hepatic gluconeogenesis by 2,3,7,8-tetrachlorodibenzo-p-dioxin and of nicotinamide as a corrective agent for this effect. | 2010 Dec 10 |
|
| Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. | 2010 Feb 10 |
|
| Triazole-linked inhibitors of inosine monophosphate dehydrogenase from human and Mycobacterium tuberculosis. | 2010 Jun 24 |
|
| Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines. | 2010 Oct 6 |
|
| Disruption of adaptive energy metabolism and elevated ribosomal p-S6K1 levels contribute to INCL pathogenesis: partial rescue by resveratrol. | 2011 Mar 15 |
|
| Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. | 2011 Mar 7 |
|
| Inactivation of porcine kidney betaine aldehyde dehydrogenase by hydrogen peroxide. | 2011 May 30 |
|
| NADH fluorescence lifetime analysis of the effect of magnesium ions on ALDH2. | 2011 May 30 |
|
| Murine hepatic aldehyde dehydrogenase 1a1 is a major contributor to oxidation of aldehydes formed by lipid peroxidation. | 2011 May 30 |
|
| NAD(P)H:quinone oxidoreductase 1 (NQO1) competes with 20S proteasome for binding with C/EBPα leading to its stabilization and protection against radiation-induced myeloproliferative disease. | 2012 Dec 7 |
|
| Differences in susceptibility to inactivation of human aldehyde dehydrogenases by lipid peroxidation byproducts. | 2012 Mar 19 |
|
| A second target of benzamide riboside: dihydrofolate reductase. | 2012 Nov |
|
| Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. | 2013 |
|
| Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. | 2013 Dec |
|
| Resveratrol induces a mitochondrial complex I-dependent increase in NADH oxidation responsible for sirtuin activation in liver cells. | 2013 Dec 20 |
|
| Fluorescence lifetime analysis and effect of magnesium ions on binding of NADH to human aldehyde dehydrogenase 1. | 2013 Feb 25 |
|
| Catalytic contribution of threonine 244 in human ALDH2. | 2013 Feb 25 |
|
| Biocatalytic production of alpha-hydroxy ketones and vicinal diols by yeast and human aldo-keto reductases. | 2013 Feb 25 |
|
| NAD(+) administration decreases doxorubicin-induced liver damage of mice by enhancing antioxidation capacity and decreasing DNA damage. | 2014 Apr 5 |
|
| Resveratrol delays Wallerian degeneration in a NAD(+) and DBC1 dependent manner. | 2014 Jan |
|
| Reduction of sulfamethoxazole hydroxylamine (SMX-HA) by the mitochondrial amidoxime reducing component (mARC). | 2014 Oct 20 |
|
| Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships. | 2015 Jun 5 |
|
| Development of a high-throughput in vitro assay to identify selective inhibitors for human ALDH1A1. | 2015 Jun 5 |
|
| Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3. | 2015 Jun 5 |
|
| Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. | 2015 Mar |
Patents
Sample Use Guides
Dosage requirements and response time vary from individual to individual. Optimal dosage
should be established individually. A daily dosage of 2.5 mg shows results in healthy people;
people with neurological disorders may require higher amounts. Enada tablets should always
be taken whole with half a glass of water only on an empty stomach, 20-30 minutes before a
meal, preferably in the morning.
Enada is available as a dietary supplement in the U.S.A. in 2.5 mg and 5 mg tablet form.
Nutritional and Energy Enhancement
2.5 to 5 mg daily or every other day depending upon individual response.
Therapeutic Treatment
10 to 15 mg daily, depending upon individual requirements and the guidance of your
physician or health-care professional.
Route of Administration:
Oral
Oochlear organotypic cultures were treated with different doses of Mn (0.5-3.0 mM) alone or combined with 20 mM NADIDE (NAD). Results demonstrate that the percentage of hair cells, auditory nerve fibers (ANF) and SGN decreased with increasing Mn concentration. The addition of 20 mM NAD did not significantly reduce hair cells loss in the presence of Mn, whereas the density of ANF and SGN increased significantly in the presence of NAD. NAD suppressed Mn-induced TUNEL staining and caspase activation suggesting it prevents apoptotic cell death.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:00:57 GMT 2023
by
admin
on
Sat Dec 16 05:00:57 GMT 2023
|
| Record UNII |
NR2O7P57YA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1184-16-3
Created by
admin on Sat Dec 16 05:00:57 GMT 2023 , Edited by admin on Sat Dec 16 05:00:57 GMT 2023
|
PRIMARY | |||
|
NR2O7P57YA
Created by
admin on Sat Dec 16 05:00:57 GMT 2023 , Edited by admin on Sat Dec 16 05:00:57 GMT 2023
|
PRIMARY | |||
|
2724369
Created by
admin on Sat Dec 16 05:00:57 GMT 2023 , Edited by admin on Sat Dec 16 05:00:57 GMT 2023
|
PRIMARY | |||
|
DTXSID30861580
Created by
admin on Sat Dec 16 05:00:57 GMT 2023 , Edited by admin on Sat Dec 16 05:00:57 GMT 2023
|
PRIMARY | |||
|
20273
Created by
admin on Sat Dec 16 05:00:57 GMT 2023 , Edited by admin on Sat Dec 16 05:00:57 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
